Recent Metastatic Stage IV (D) Prostate Cancer News

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (August 27, 2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA... Continue Reading

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (June 16, 2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a... Continue Reading

Zytiga Prolongs Time to Pain Progression (January 31, 2014)

The addition of Zytiga® (abiraterone) to prednisone significantly delayed patient-reported pain progression and health-related quality-of-life deterioration compared with prednisone alone in chemotherapy-naive... Continue Reading

Xofigo Improves Bone and Pain in Prostate Cancer (October 14, 2013)

Patients with hormone-refractory prostate cancer and bone metastases had significant improvement in skeletal- and pain-related outcomes when treated with Xofigo® (radium-223), according to the results... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results... Continue Reading

Next Page »